NCT06624787 Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care
| NCT ID | NCT06624787 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Liverpool School of Tropical Medicine |
| Condition | Crimean-Congo Haemorrhagic Fever |
| Study Type | INTERVENTIONAL |
| Enrollment | 492 participants |
| Start Date | 2026-05-04 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 492 participants in total. It began in 2026-05-04 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this medical device diagnostic evaluation study is to determine if this novel lateral flow device can detect Crimean-Congo Hemorrhagic Fever (CCHF) at the point of care in secondary health care clinics in Turkey. The main outcome is to determine the sensitivity and specificity of the tests for CCHF in samples of whole blood, serum and capillary blood compared to a gold-standard of PCR for participants that present at 4 endemic sites secondary health care clinics in Turkey in 492 adults who are suspected to have been infected with CCHF. The study aims to hopes to achieve at least the minimum required sensitivity of 90 % and specificity of 80 % as required by the WHO.
Eligibility Criteria
Inclusion Criteria: Participants aged 18 years or older Suspected CCHF infection that requires a RT-PCR diagnosis and venous blood draw Willingness to comply with study procedures and consent to the study Presents at 1 of 4 listed sites Exclusion Criteria: * In the investigators opinion should not be enrolled onto study (e.g., medical prudence or capacity)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06624787 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Crimean-Congo Haemorrhagic Fever. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06624787 currently recruiting?
Yes, NCT06624787 is actively recruiting participants. Contact the research team at ravi.lad@lstmed.ac.uk for enrollment information.
Where is the NCT06624787 trial being conducted?
This trial is being conducted at Erzurum, Turkey (Türkiye), Erzurum, Turkey (Türkiye), Kastamonu, Turkey (Türkiye), Samsun, Turkey (Türkiye) and 2 additional locations.
Who is sponsoring the NCT06624787 clinical trial?
NCT06624787 is sponsored by Liverpool School of Tropical Medicine. The trial plans to enroll 492 participants.